NEW YORK (GenomeWeb) – Courtagen Life Sciences announced yesterday that it has signed an agreement to collaborate with Astellas Pharma for the early-stage development of therapeutics for mitochondrial disease.

Mitochondrial disease is a class of rare genetic disorders caused when cellular mitochondria do not properly produce energy. Its symptoms vary from patient to patient, but can include muscle weakness, neurological problems, developmental delays, and increased risk of infection.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.